Related Experiment Video
Updated: Apr 21, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
11.1K
CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY
Alexandra M Nicholson1, Adriana Ferreira1
1Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
Cognitive Sciences
|October 24, 2014
Summary
Cholesterol metabolism, particularly the apolipoprotein E4 (ApoE4) allele, is linked to Alzheimer's disease (AD) pathogenesis. Research explores how cholesterol influences AD hallmarks and neuronal vulnerability, suggesting cholesterol-lowering drugs as a potential preventative strategy.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Alzheimer's disease (AD) is a growing neurocognitive disorder primarily affecting the elderly population.
- Sporadic AD, the most common form, lacks a clear unifying cause, unlike rare genetically inherited forms.
- The apolipoprotein E4 (ApoE4) allele is the strongest genetic risk factor for sporadic AD.
Purpose of the Study:
- To review the molecular mechanisms linking cholesterol metabolism to Alzheimer's disease pathogenesis.
- To investigate the role of cholesterol in the development of AD's pathological hallmarks.
- To explore the potential of cholesterol-lowering drugs in preventing or mitigating AD.
Main Methods:
- Literature review focusing on studies investigating cholesterol's role in AD.
- Analysis of the apolipoprotein E4 (ApoE4) allele's function in cholesterol transport and neuronal health.
- Examination of how cholesterol impacts cellular susceptibility to AD-related damage.
Main Results:
- Cholesterol plays a significant role in the production of pathological hallmarks associated with Alzheimer's disease.
- Elevated cholesterol levels or altered cholesterol transport may increase neuronal vulnerability to AD insults.
- The apolipoprotein E4 (ApoE4) protein's involvement in cholesterol transport is a key factor in AD risk.
Conclusions:
- Cholesterol metabolism is intrinsically linked to the development and progression of Alzheimer's disease.
- Targeting cholesterol pathways, potentially through cholesterol-lowering drugs, represents a promising avenue for AD prevention.
- Further research into the precise mechanisms of cholesterol's influence on neurodegeneration is warranted.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
7
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
7
01:29Alzheimer Disease l: Introduction
7
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
7
03:03Amyloid Fibrils
10.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.1K
03:03Amyloid Fibrils
5.2K
5.2K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K